Horn Heike, Jurinovic Vindi, Leich Ellen, Kalmbach Sabrina, Bausinger Julia, Staiger Annette M, Kurz Katrin S, Möller Peter, Bernd Heinz-Wolfram, Feller Alfred C, Koch Karoline, Klapper Wolfram, Stein Harald, Hansmann Martin-Leo, Hartmann Sylvia, Scheubeck Gabriel, Dreyling Martin, Hiddemann Wolfgang, Herfarth Klaus, Engelhard Marianne, Rosenwald Andreas, Hoster Eva, Ott German
Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tuebingen, Germany.
Hemasphere. 2022 Aug 10;6(9):e767. doi: 10.1097/HS9.0000000000000767. eCollection 2022 Sep.
Recently, we have developed novel highly promising gene expression (GE) classifiers discriminating localized nodal (LFL) from systemic follicular lymphoma (SFL) with prognostic impact. However, few data are available in LFL especially concerning hotspot genetic alterations that are associated with the pathogenesis and prognosis of SFL. A total of 144 LFL and 527 SFL, enrolled in prospective clinical trials of the German Low Grade Lymphoma Study Group, were analyzed by fluorescence in situ hybridization to detect deletions in chromosomes 1p, 6q, and 17p as well as translocations to determine their impact on clinical outcome of LFL patients. The frequency of chromosomal deletions in 1p and 17p was comparable between LFL and SFL, while 6q deletions and translocations more frequently occurred in SFL. A higher proportion of 1p deletions was seen in -translocation-positive LFL, compared with -translocation-negative LFL. Deletions in chromosomes 1p, 6q, and 17p predicted clinical outcome of patients with SFL in the entire cohort, while only deletions in chromosome 1p retained its negative prognostic impact in R-CHOP-treated SFL. In contrast, no deletions in one of the investigated genetic loci predicted clinical outcome in LFL. Likewise, the presence or absence of translocations had no prognostic impact in LFL. Despite representing a genetic portfolio closely resembling SFL, LFL showed some differences in deletion frequencies. translocation and 6q deletion frequency differs between LFL and SFL and might contribute to distinct genetic profiles in LFL and SFL.
最近,我们开发了新型且极具前景的基因表达(GE)分类器,可区分局限性滤泡性淋巴瘤(LFL)和系统性滤泡性淋巴瘤(SFL),并具有预后意义。然而,关于LFL的数据很少,尤其是与SFL的发病机制和预后相关的热点基因改变方面。对德国低度淋巴瘤研究组前瞻性临床试验中纳入的144例LFL和527例SFL进行荧光原位杂交分析,以检测1p、6q和17号染色体的缺失以及易位情况,从而确定它们对LFL患者临床结局的影响。LFL和SFL中1p和17号染色体的缺失频率相当,而6q缺失和易位在SFL中更常见。与易位阴性的LFL相比,易位阳性的LFL中1p缺失的比例更高。在整个队列中,1p、6q和17号染色体的缺失可预测SFL患者的临床结局,而在接受R-CHOP治疗的SFL中,只有1号染色体的缺失保留了其负面预后影响。相比之下,在研究的基因位点中,没有一个位点的缺失可预测LFL的临床结局。同样,易位的存在与否对LFL的预后没有影响。尽管LFL的基因组合与SFL非常相似,但LFL在缺失频率上仍存在一些差异。LFL和SFL之间的易位和6q缺失频率不同,这可能导致LFL和SFL具有不同的基因特征。